Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

BACKGROUND: The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received conditional approval in the European Union: Sofosbuvir and Ribavirin for 24 week...

Descripción completa

Detalles Bibliográficos
Autores principales: Gissel, Christian, Götz, Georg, Mahlich, Jörg, Repp, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520276/
https://www.ncbi.nlm.nih.gov/pubmed/26223310
http://dx.doi.org/10.1186/s12879-015-1048-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520276/
https://www.ncbi.nlm.nih.gov/pubmed/26223310
http://dx.doi.org/10.1186/s12879-015-1048-z

Ejemplares similares